Table 1:
Baseline characteristics of patients with V600E versus V600K metastatic melanoma (BRAFi+/−MEKi cohort)
| Characteristics | V600E (n=78) | V600K (n=15) | P-value |
|---|---|---|---|
| Age (years) | |||
| Median | 56.5 | 58.0 | 0.418 |
| Gender (N, %) | 0.5786 | ||
| Female | 33 (42%) | 5 (33%) | |
| Male | 45 (58%) | 10 (67%) | |
| AJCC stage1 (N, %) | 1 | ||
| IIIC-M1b | 19 (24%) | 3 (20%) | |
| M1c | 59 (76%) | 12 (80%) | |
| LDH (N, %) | 0.3563 | ||
| Normal | 57 (73%) | 9 (60%) | |
| Elevated | 21 (27%) | 6 (40%) | |
| ECOG (N, %) | 1 | ||
| 0 | 47 (60%) | 9 (60%) | |
| ≥1 | 31 (40%) | 6 (40%) | |
| Treatment (N, %) | 0.3162 | ||
| BRAFi | 62 (80%) | 10 (67%) | |
| BRAFi + MEKi | 16 (20%) | 5 (33%) |
1
AJCC v7 anatomic staging, excluding LDH and brain metastases